RxDoctor Payments Data

Ana Seijas, MD

Internal Medicine · Palatka, FLNPI 1679677249

Payments from drug & device makers

$3,215in general payments, 2019–2025

Across 177 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$452
  • AbbVie$409
  • Lilly USA, LLC$363
  • AstraZeneca$203
  • Amgen$200
  • Pfizer$178
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,14898%
  • Education$70%
  • Gifts$592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,215 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$729
Medicare patients
20
Services billed
29

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide146$261,669
JardianceEmpagliflozin130$182,887
FarxigaDapagliflozin Propanediol130$166,723
MounjaroTirzepatide86$149,490
EliquisApixaban53$41,512
MyrbetriqMirabegron26$24,938
RybelsusSemaglutide13$23,569
Breo ElliptaFluticasone/Vilanterol33$23,069
XareltoRivaroxaban11$15,756
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$12,531
BelsomraSuvorexant22$9,320
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$8,280
TradjentaLinagliptin11$7,559
Humalog Kwikpen U-100Insulin Lispro15$5,141
Albuterol Sulfate HfaAlbuterol Sulfate129$4,617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$452$285,238159 claims
Boehringer IngelheimJardiance, Tradjenta$79$190,446141 claims
AstraZenecaFarxiga, Breztri Aerosphere$203$179,254148 claims
Lilly USA, LLCMounjaro$363$149,49086 claims
PfizerEliquis$178$41,51253 claims
Astellas Pharma US IncMyrbetriq$64$24,93826 claims
GSKBreo Ellipta$113$23,06933 claims
MerckBelsomra$11$9,32022 claims
AbbVieSynthroid$409$2,97632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Palatka

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →